Effectiveness and Safety of Bulevirtide (BLV) Therapy in Patients With Chronic Hepatitis Delta (CHD) in Italy (D-SHIELD)

Abroad (travel likely)Recruiting

Conditions

Hepatitis D

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Division of Gastroenterology and Hepatology, Milan, Italy., Milan, MI, Italy
Contact: Study coordinator (Pietro Lampertico, MD) · pietro.lampertico@unimi.it · 0255035432

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide

Chronic Hepatitis D

Abroad (travel likely)RecruitingPHASE2, PHASE3

Graz, Austria · Innsbruck, Austria

A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)

Chronic Hepatitis D Infection

Abroad (travel likely)RecruitingPHASE3

Graz, Austria · Sankt Pölten, Austria

Oral-Periodontal Evaluation and Assessment of Oral Fluid Biomarkers in Patients With Hepatitis B+D

HEPATITIS B CHRONIC · Hepatitis D · Periodontitis

Abroad (travel likely)Recruiting

Craiova, Romania · Craiova, Romania

Immunological and Virological Characterization of Patients With Chronic HBV-HDV Infection: Outcomes and Response to Bulevirtide Treatment

Hepatitis D

Abroad (travel likely)Recruiting

Milan, Italy